SLC38A2 and cancer: Collectively, our data reveal that oncogenic KRAS alters the expression of AATs such as SLC1A5/ASCT2, SLC7A5/LAT1, and SLC38A2/SNAT2 and thereby increase the uptake of AAs to support cancer cell proliferation through mTOR activation.